Poster Presentations

Presented at 36th EORTC-NCI-AACR 2024

TT125-802, a highly selective bromodomain inhibitor of CBP/p300, in patients with advanced solid tumors: an update on the phase I study

Boni, et al.

Presented at AACR 2024

An image-based phenotypic screen identified the bromodomain of CBP/p300 as new cancer drug resistance target and enabled the development of the clinical candidate TT125-802

Gruber, et al.

Presented at AACR 2023

TT125-802 is a potent and highly selective CBP/p300 bromodomain inhibitor for the treatment of castration resistant prostate cancer and hematological malignancies

Laudato et al.

Presented at AACR 2023

Targeting adaptive resistance to EGFR and KRAS G12C inhibitors by TT125-802, a novel and specific CBP/p300 bromodomain inhibitor

Bohnacker, et al.